Financial reports
20-F
2023 FY
Annual report (foreign)
12 Apr 24
20-F
2022 FY
Annual report (foreign)
24 Mar 23
20-F
2021 FY
Annual report (foreign)
25 Mar 22
20-F/A
2020 FY
Annual report (foreign) (amended)
6 Aug 21
20-F
2020 FY
Annual report (foreign)
23 Apr 21
20-F
2019 FY
Annual report (foreign)
16 Apr 20
20-F
2018 FY
Annual report (foreign)
29 Apr 19
Current reports
6-K
Aslan Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab In Dupilumab-experienced Atopic Dermatitis Patients
22 Apr 24
6-K
Aslan Pharmaceuticals Announces Receipt of Nasdaq Notice
19 Apr 24
6-K
Amendment No. 2 to the Open Market Sale Agreementsm
12 Apr 24
6-K
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 Apr 24
6-K
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
13 Mar 24
6-K
ASLAN PHARMACEUTICALS PROVIDES TREK-DX STUDY UPDATE AND HIGHLIGHTS potENTIAL of EBLASAKIMAB in DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS
11 Mar 24
6-K
Current report (foreign)
24 Jan 24
6-K
Aslan Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
8 Jan 24
6-K
Current report (foreign)
22 Dec 23
6-K
Current report (foreign)
8 Dec 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
12 Apr 24
S-8
Registration of securities for employees
12 Apr 24
D
$5.00 mm in options / securities to be acquired, sold $5.00 mm, 4 investors
28 Mar 24
F-3
Shelf registration (foreign)
25 Mar 24
424B5
Prospectus supplement for primary offering
14 Mar 24
424B5
Prospectus supplement for primary offering
6 Jul 23
F-6EF
Automatic registration for ADRs (foreign)
26 Apr 23
D
$100.00 mm in equity / options / securities to be acquired, sold $20.00 mm, 7 investors
26 Apr 23
F-3
Shelf registration (foreign)
24 Mar 23
F-3
Shelf registration (foreign)
24 Mar 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
1 Apr 24
EFFECT
Notice of effectiveness
7 Apr 23
EFFECT
Notice of effectiveness
7 Apr 23
CORRESP
Correspondence with SEC
4 Apr 23
CORRESP
Correspondence with SEC
4 Apr 23
UPLOAD
Letter from SEC
30 Mar 23
UPLOAD
Letter from SEC
30 Mar 23
CT ORDER
Confidential treatment order
3 Nov 22
CT ORDER
Confidential treatment order
3 Nov 22
EFFECT
Notice of effectiveness
1 Apr 21
Ownership
SC 13G
INTRACOASTAL CAPITAL, LLC
21 Mar 24
SC 13G
Lind Global Fund II LP
19 Mar 24
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G
UBS Group AG
6 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
2 Jan 24
SC 13G/A
TANG CAPITAL PARTNERS LP
13 Jul 23
SC 13G
K2 HealthVentures Equity Trust LLC
20 Mar 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
6 Mar 23
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 23